WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the 43rd Annual J.P. Morgan Healthcare Conference, being held January 13 – 16 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 14 at 1:30 p.m. PT. A live webcast of the conference presentation will be accessible through Repl ...

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its CTech™ SoloVPE® PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers. The SoloVPE PLUS System is engineered to offer unparalleled accuracy, speed, and ease-of-use for at-line ultraviolet-visible (UV-Vis) concentration measurement in co ...

It has been about a month since the last earnings report for Repligen (RGEN) . Shares have added about 3.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Repligen due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Repligen’s Q3 Earnings & Revenues Surpass EstimatesRe ...

WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2023 Corporate Sustainability Report and related reporting framework disclosures. Themed “Advancing Impacts”, this newly reformatted report streamlines the company’s progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Commun ...

营收情况 - 2024年三季度产品营收较2023年同期增长9.7%达1370万美元[105] - 2024年三季度产品营收增长主要源于过滤业务营收增长1230万美元[105] 成本与费用 - 2024年三季度总成本和运营费用较2023年同期增长19.2%[108] - 2024年三季度销售、一般和管理费用较2023年同期增长36.0%[108] - 2024年三季度研发费用较2023年同期下降8.2%[111] - 2024年三季度成本下降部分源于材料和管理费用下降500万美元[109] - SG&A成本在2024年第三季度增加2000万美元涨幅36% 九个月增加4190万美元涨幅26.1%[113] - 2024年第三季度和九个月的增量股票补偿费用分别为1740万美元和2240万美元[113] - 排除增量股票补偿费用 2024年第三季度SG&A费用增加260万美元[113] - 排除增量股票补偿费用 2024年九个月SG&A费用增加1950万美元[113] 企业并购 - 2024年9月拟收购Tantti Laboratory Inc[99] - 2023年4月完成对FlexBiosys, Inc.的收购[101] - 2023年10月以约1.73亿美元现金和公司股权完成对Metenova Holding AB的收购[102] 利润相关 - 2024年三季度毛利润率为50.0%2023年同期为25.9%[110] 财务收支 - 2024年第三季度和九个月投资收入分别增加250万美元和940万美元[115] - 2024年第三季度和九个月利息费用分别为5122美元和15269美元[115] - 2024年第三季度和九个月债务发行成本摊销分别为429美元和1200美元[115] - 2024年第三季度和九个月其他收入净额分别减少7美元和6826美元[115] - 2024年第三季度和九个月所得税收益分别为 - 0.5百万美元和3.2百万美元[120] 现金及现金等价物 - 2024年9月30日现金及现金等价物为7.84亿美元[122] - 2023年12月14日公司通过私募发行6亿美元2023年票据[123] - 2024年前三季度经营活动提供现金1.362亿美元相比2023年同期的8485.3万美元有所增加[124][125] - 2024年前三季度投资活动使用现金2162.1万美元2023年同期提供4663万美元[127] - 2024年前三季度融资活动使用现金8440万美元2023年同期使用1920万美元[128] - 汇率变动对2024年前三季度现金及现金等价物影响为增加239.5万美元[129] 企业财务状况 - 截至2023年12月31日公司有联邦净经营亏损结转3110万美元等[131] - 公司认为当前现金余额足以满足未来24个月现金需求[129] - 预计本财年剩余时间运营费用将增加[130] - 公司计划继续投资生物加工业务及相关研发活动[130] - 公司可能需要寻求额外融资以满足流动性需求[130]

Repligen Corporation (NASDAQ:RGEN) Q3 2024 Results Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Sondra Newman - Vice President, Global Head of Investor Relations Olivier Loeillot - President and Chief Executive Officer Jason Garland - Chief Financial Officer Conference Call Participants Dan Leonard - UBS Dan Arias - Stifel Rachel Vatnsdal - J.P. Morgan Puneet Souda - Leerink Partners Matt Larew - William Blair & Company Jacob Johnson - Stephens Inc. Conor McNamara - RBC Capital ...

Repligen Corporation (RGEN) reported third-quarter 2024 adjusted earnings per share of 43 cents, which beat the Zacks Consensus Estimate of 34 cents. The company recorded adjusted earnings of 23 cents per share in the year-ago quarter.Total revenues were $154.9 million, up 10% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 7% organically. The reported figure also beat the Zacks Consensus Estimate of $153.1 million.This increase in total ...

Repligen Corp RGEN released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the consensus of $153.23 million.Olivier Loeillot, president and CEO of Repligen, said, "I'm pleased to report strong third-quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and ...

Repligen (RGEN) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 26.47%. A quarter ago, it was expected that this drug developer would post earnings of $0.33 per share when it actually produced earnings of $0.33, delivering no surprise.Over the last four quarters, the company has surpa ...

营收相关 - 2024年第三季度营收为1.55亿美元同比增长10%[1] - CDMO营收和订单同比增长约20%[1] - 整体订单摄入量比销售额高4%[1] - 2024全年营收指引收窄至6.30 - 6.39亿美元[1] - 新业务模式季度营收同比增长20%[3] - CDMO和设备营收同比分别增长约20%和6%[3] - 2024年前三季度总报告收入（GAAP）较2023年同期增长0%[18] - 2024年第三季度总报告收入（GAAP）较2023年同期增长10%[18] - 2024年前三季度有机收入增长（NON - GAAP）较2023年同期下降2%[17] - 2024年第三季度有机收入增长（NON - GAAP）较2023年同期增长7%[17] - 2024年9月止九个月净收入（GAAP）83.55亿美元2023年同期520.46亿美元[22] - 2024年9月止三个月净亏损（GAAP）6.53亿美元2023年同期净收入169.23亿美元[22] - 2024年全年GAAP净收入指引低至14000美元 高至18000美元[27] - 2024年全年调整后净收入（非GAAP）指引85000美元至89000美元[27] 利润率相关 - 2024年第三季度GAAP毛利润率为50.0%[5] - 2024年第三季度调整后（非GAAP）运营利润率为14.9%[5] - 2024年前三季度调整后运营（EBIT）利润率为12.2%[19] - 2023年前三季度调整后运营（EBIT）利润率为12.5%[19] - 2024年9月止三个月调整后EBITDA（非GAAP）32005美元 利润率20.7%[22] - 2024年9月止九个月调整后EBITDA（非GAAP）82187美元 利润率17.6%[22] 企业发展相关 - 宣布收购色谱创新企业Tantti Laboratory Inc.[3] - 在沃尔瑟姆开设新的客户导向的Repligen培训与创新中心[3] 每股收益相关 - 2024年前三季度调整后净收入（NON - GAAP）为6367.4万美元[20] - 2023年前三季度调整后净收入（NON - GAAP）为6602.7万美元[20] - 2024年第三季度调整后每股收益（NON - GAAP） - 稀释为0.43美元[21] - 2023年第三季度调整后每股收益（NON - GAAP） - 稀释为0.23美元[21] 费用相关 - 2024年9月止三个月研发费用（GAAP）9710美元 调整后（非GAAP）9626美元[24] - 2024年9月止九个月研发费用（GAAP）31523美元 调整后（非GAAP）30874美元[24] - 2024年9月止三个月销售管理费用（GAAP）75610美元 调整后（非GAAP）45764美元[25] - 2024年9月止九个月销售管理费用（GAAP）202894美元 调整后（非GAAP）147089美元[25]